Biosynex Valuation Multiples

Biosynex is valued at $17M as of October 2026, a 0.7x revenue multiple. In the last 12 months, Biosynex revenue was $110M and Biosynex EBITDA was ($16M).

Biosynex Overview

About Biosynex

Biosynex SA develops, manufactures and markets in-vitro diagnostic devices and healthcare products. Its diagnostic portfolio includes rapid diagnostic tests, molecular biology kits, self-tests, immunoblot and point-of-care diagnostic solutions used for screening, diagnosis and patient monitoring. The company provides products for healthcare professionals as well as general-public and pharmacy markets in France and internationally.


Founded

2005

HQ

France

Employees

273

Financials (LTM)

Revenue: $110M
EBITDA: ($16M)

EV

$77M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Biosynex Financials

Biosynex reported last 12-month revenue of $110M and negative EBITDA of ($16M).

In the same LTM period, Biosynex generated ($16M) in EBITDA losses and had net loss of ($25M).


Biosynex P&L

In the most recent fiscal year, Biosynex reported revenue of $107M and EBITDA of ($2M).

Biosynex is unprofitable as of last fiscal year, with gross margin of 55%, EBITDA margin of (2%), and net margin of (61%).

See analyst estimates for Biosynex
LTMLast FY202320242025202620272028
Revenue$110M$107M$108M$118M$107M
Gross Profit-$59M$57M$67M$59M
Gross Margin-55%53%57%55%
EBITDA($16M)($2M)($25M)($21M)($2M)
EBITDA Margin(14%)(2%)(23%)(18%)(2%)
EBIT Margin(22%)(67%)(40%)(36%)(67%)
Net Profit($25M)($65M)($43M)($50M)($65M)
Net Margin(23%)(61%)(40%)(43%)(61%)
Net Debt-$60M---

Financial data powered by Morningstar, Inc.

Biosynex Stock Performance

Biosynex has current market cap of $17M, and enterprise value of $77M.

Market Cap Evolution


Biosynex's stock price is $0.94.

Biosynex share price decreased by 5.0% in the last 30 days, and increased by 28.9% in the last year.

Biosynex has an EPS (earnings per share) of $-3.55.

See more trading valuation data for Biosynex
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$77M$17M0.0%-5.0%-11.1%28.9%$-3.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Biosynex Valuation Multiples

Biosynex trades at 0.7x EV/Revenue multiple, and (4.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Biosynex

Biosynex Financial Valuation Multiples

As of October 19, 2026, Biosynex has market cap of $17M and EV of $77M.

Biosynex has a P/E ratio of (0.7x).

LTMLast FY202320242025202620272028
EV/Revenue0.7x0.7x0.7x0.7x0.7x
EV/EBITDA(4.9x)(40.5x)(3.1x)(3.7x)(40.5x)
EV/EBIT(3.2x)(1.1x)(1.8x)(1.8x)(1.1x)
EV/Gross Profit-1.3x1.4x1.2x1.3x
P/E(0.7x)(0.3x)(0.4x)(0.3x)(0.3x)
EV/FCF-(8.0x)(1.4x)(4.4x)(8.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Biosynex Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Biosynex Margins & Growth Rates

In the most recent fiscal year, Biosynex reported gross margin of 55%, EBITDA margin of (2%), and net margin of (61%).

See estimated margins and future growth rates for Biosynex

Biosynex Margins

Last FY20242025202720282029
Gross Margin55%57%55%
EBITDA Margin(2%)(18%)(2%)
EBIT Margin(67%)(36%)(67%)
Net Margin(61%)(43%)(61%)
FCF Margin(9%)(15%)(9%)

Biosynex Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth9%(9%)
Gross Profit Growth17%(12%)
EBITDA Growth(17%)(91%)
EBIT Growth(3%)69%
Net Profit Growth17%30%
FCF Growth(70%)(45%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Biosynex Operational KPIs

Biosynex's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for Biosynex
LTMLast FY202320242025202620272028
Rule of 409%----
Bessemer Rule of X43%----
Revenue per Employee-$0.4M---
Opex per Employee-$0.5M---
Opex to Revenue-122%93%93%122%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Elbit Realestate$12M$981K4.6x-57.4x-
European Medical Solutions$56M$5M0.6x-7.0x-
Lifeward$22M($19M)0.7x0.6x(0.8x)-
Labo Euromedis$46M$637K0.1x-9.8x-
Promimic$4M($295K)3.6x-(54.8x)-
Baird Medical Investment$23M($25M)1.6x-(1.5x)-
Lifecare$12K($12M)1250.2x174.4x(1.3x)(1.8x)
EBM Technologies$8M$850K2.1x-19.3x-

This data is available for Pro users. Sign up to see all Biosynex competitors and their valuation data.

Start Free Trial

Acquisitions by Biosynex

Biosynex has acquired 6 companies to date.

Last acquisition by Biosynex was on June 13th 2023. Biosynex acquired ProciseDx for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Biosynex

ProciseDx
PARA’KITO
Avalun
SR2B SA
Description
ProciseDx is a diagnostics company specializing in point-of-care testing devices for rapid, accurate results. The platform delivers quantitative assays for biomarkers in minutes, enabling immediate clinical decisions without lab delays. Focused on infectious diseases and cardiac markers, ProciseDx devices integrate microfluidics and immunoassay technology. Based in Rockville, Maryland, it partners with healthcare providers to streamline patient workflows in clinics and emergency settings.
PARA’KITO is a Paris-headquartered company specializing in natural insect repellent technology. The firm manufactures wearable devices like bracelets and patches using a plant-based active ingredient effective against mosquitoes transmitting dengue, Zika, and malaria. PARA’KITO products are distributed in over 40 countries through pharmacies and retailers such as Boots and Walgreens, with clinical studies confirming up to eight hours of protection.
Avalun creates the Labpad, a portable in vitro diagnostic device yielding rapid test results from tiny sample volumes.
SR2B SA is a biotechnology firm developing reagents for microbiology and parasitology. Through http://www.sr2b.fr/, it produces parasitic antigens, fungal diagnostics, monoclonal antibodies, and lyophilized bioproducts with microparticle coupling for research labs in Europe.
HQ CountryUnited StatesUnited StatesFranceFrance
HQ City
San Diego, CA
Fort Lauderdale, FL
Grenoble
Angers
Deal Date13 Jun 202320 Apr 20223 May 20217 Jul 2017
Valuationundisclosedundisclosed$12Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Biosynex acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Biosynex

When was Biosynex founded?Biosynex was founded in 2005.
Where is Biosynex headquartered?Biosynex is headquartered in France.
How many employees does Biosynex have?As of today, Biosynex has over 273 employees.
Who is the CEO of Biosynex?Biosynex's CEO is Larry Abensur.
Is Biosynex publicly listed?Yes, Biosynex is a public company listed on Euronext Paris.
What is the stock symbol of Biosynex?Biosynex trades under ALBIO ticker.
When did Biosynex go public?Biosynex went public in 2011.
Who are competitors of Biosynex?Biosynex main competitors include Elbit Realestate, European Medical Solutions, Lifeward, Labo Euromedis, Promimic, Baird Medical Investment, Lifecare, EBM Technologies, Accuray, Impedimed.
What is the current market cap of Biosynex?Biosynex's current market cap is $17M.
What is the current revenue of Biosynex?Biosynex's last 12 months revenue is $110M.
What is the current revenue growth of Biosynex?Biosynex revenue growth (NTM/LTM) is 23%.
What is the current EV/Revenue multiple of Biosynex?Current revenue multiple of Biosynex is 0.7x.
Is Biosynex profitable?No, Biosynex is not profitable.
What is the current EBITDA of Biosynex?Biosynex has negative EBITDA and is not profitable.
What is Biosynex's EBITDA margin?Biosynex's last 12 months EBITDA margin is (14%).
What is the current EV/EBITDA multiple of Biosynex?Current EBITDA multiple of Biosynex is (4.9x).
How many companies Biosynex has acquired to date?As of October 2026, Biosynex has acquired 6 companies.
What was the largest acquisition by Biosynex?$12M acquisition of Avalun on 3rd May 2021 was the largest M&A Biosynex has done to date.
What companies Biosynex acquired?Biosynex acquired Avalun, Fumouze Diagnostics, SR2B SA, PARA’KITO, Dectra Pharm, and ProciseDx.
In how many companies Biosynex has invested to date?Biosynex hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Biosynex

Lists including Biosynex

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial